Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azadirachta indica leaf, commonly known as Neem, is a botanical extract derived from the leaves of the Neem tree. It contains a complex mixture of bioactive phytochemicals, including limonoids (such as nimbolide and azadirachtin), triterpenoids (nimbin), flavonoids, and alkaloids. The extract is widely studied for its immunomodulatory, anti-inflammatory, and anticancer properties. Mechanistically, Neem leaf preparations (NLP) have been shown to enhance the cytotoxic activity of natural killer (NK) cells and stimulate the release of interleukin-12 (IL-12) from macrophages. These effects are mediated through the activation of the p38 MAPK pathway and the upregulation of CD40 and CD40L. Additionally, the extract modulates several key signaling pathways involved in cell survival and inflammation, including NF-κB, PI3K/Akt, and IGF signaling. While not an approved pharmaceutical drug, it is a staple of traditional Ayurvedic and Unani medicine and is frequently used in over-the-counter products and dietary supplements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azadirachta indica leaf.